The anti-multiple myeloma effect of HDAC6 inhibition in combinations with proteosome inhibitors is a well-established HDAC6-targeting drug combination resulting in cell death by inactivating the cell responses that deal with cytotoxic proteins [70]. Here, HDAC6 is linked to AL amyloidosis.